Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`Filed on behalf of Patent Owner Genentech, Inc. by:
`
`
`David L. Cavanaugh (Reg. No. 36,476)
`Rebecca A. Whitfield (Reg. No. 73,756)
`Robert J. Gunther, Jr. (Pro Hac Vice to be filed)
`WILMER CUTLER PICKERING
` HALE AND DORR LLP
`1875 Pennsylvania Ave., NW
`Washington, DC 20006
`
`Adam R. Brausa (Reg. No.
`60,287)
`Daralyn J. Durie (Pro Hac Vice to be
`filed)
`Durie Tangri LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`PFIZER, INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner.
`
`
`Case IPR2017-02019
`U.S. Patent 6,339,142
`
`
`PATENT OWNER’S UNOPPOSED MOTION FOR ADMISSION
`PRO HAC VICE OF ROBERT J. GUNTHER, JR.
`
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`
`I. Statement of Precise Relief Requested
`
`Pursuant to 37 C.F.R. § 42.10(c), Patent Owner Genentech, Inc.
`
`(“Genentech”) requests that the Patent Trial and Appeal Board (the “Board”) admit
`
`Robert J. Gunther, Jr. pro hac vice in this proceeding, IPR2017-02019. Petitioner
`
`Pfizer Inc. has indicated that it does not oppose this motion.
`
`II. Statement of Facts Showing Good Cause for the Board to Recognize
`Counsel Pro Hac Vice During the Proceeding
`In accordance with 37 C.F.R. § 42.10(c), the Board may recognize counsel
`
`pro hac vice during a proceeding upon a showing of good cause, subject to the
`
`condition that lead counsel be a registered practitioner and to any other conditions
`
`as the Board may impose. Section 42.10(c) indicates that “where lead counsel is a
`
`registered practitioner, a motion to appear pro hac vice by counsel who is not a
`
`registered practitioner may be granted upon a showing that counsel is an
`
`experienced litigating attorney and has an established familiarity with the subject
`
`matter at issue in the proceeding.” The facts here establish good cause for the
`
`Board to recognize Robert J. Gunther, Jr. pro hac vice in this proceeding.
`
`1. Lead counsel, David L. Cavanaugh, is a registered practitioner. Backup
`
`counsel, Adam Brausa and Rebecca Whitfield are also registered
`
`practitioners.
`
`
`
`- 2 -
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`2. Counsel, Robert J. Gunther, Jr., is an experienced litigator and has an
`
`established familiarity with the subject matter at issue in the proceeding.
`
`Accompanying this motion as Exhibit 2015 is the Declaration of Robert J.
`
`Gunther, Jr. in Support of this Motion for Admission Pro Hac Vice
`
`(“Gunther Decl.”). In his declaration, Mr. Gunther asserts:
`
`I am a member in good standing of the Bar of New York, and am
`admitted to practice before District Courts of the Southern
`District of New York the Eastern District of New York, the
`Western District of New York, the Northern District of
`California, the District of Colorado, the Eastern District of
`Michigan, the Western District of Michigan, and the Northern
`District of Illinois. I am also admitted to practice before the U.S.
`Courts of Appeals for the Second, Ninth, Tenth, and Federal
`Circuits. I am a fellow of The American College of Trial
`Lawyers.
`
`Gunther Decl. ¶ 2 (Ex. 2015). Mr. Gunther also states that he has a long-
`
`standing relationship with Patent Owner Genentech, Inc. and its parent
`
`Roche. Gunther Decl. ¶ 11 (Ex. 2015). Mr. Gunther also demonstrates that
`
`he has a detailed working knowledge of the relevant subject matter through
`
`both prior inter partes review experience and his familiarity with antibody
`
`technologies as a result of participation as counsel in prior antibody-related
`
`patent cases. Gunther Decl. ¶ 12 (Ex. 2015).
`
`
`
`- 3 -
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`3. In his declaration, Mr. Gunther also attests to each of the listed items
`
`required by the Order – Authorizing Motion for Pro Hac Vice Admission –
`
`37 C.F.R. § 42.10 in IPR2013-00639. See Gunther Decl. ¶¶ 1-13 (Ex.
`
`2015). Mr. Gunther attests that he has read and will comply with the Office
`
`Patent Trial Practice Guide and the Board’s Rules of Practice for Trials set
`
`forth in 37 C.F.R. § 42. See id. ¶ 8. Mr. Gunther further attests that he
`
`agrees to be subject to the United States Patent and Trademark Office’s
`
`Rules of Professional Conduct as set forth in 37 C.F.R. §§ 11.101 et seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a). See id. ¶ 9.
`
`III. Conclusion
`
`For the foregoing reasons, Patent Owner respectfully requests that the Board
`
`admit Robert J. Gunther, Jr. pro hac vice in this proceeding.
`
`Date: January 2, 2018
`
`Respectfully submitted,
`
`By: /David L. Cavanaugh/
`David L. Cavanaugh
`Reg. No. 36,476
`Wilmer Cutler Pickering Hale and Dorr LLP
`1875 Pennsylvania Avenue NW
`Washington, DC 20006
`
`
`
`- 4 -
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`PATENT OWNER’S EXHIBIT LIST
`IPR2017-02019
`
`Patent Owner’s
`Exhibit Number
`2001
`
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit Name
`
`David Holzman, Gene Therapy for HER-2-Related Cancer,
`MOLECULAR MED. TODAY 138 (1996)
`Russ Hoyle, Genentech Is Poised for an Anti-Cancer
`Breakthrough, 16 NATURE BIOTECHNOLOGY 887 (1998)
`Jatinderpal Kalsi et al., Structure-Function Analysis and the
`Molecular Origins of Anti-DNA Antibodies in Systemic Lupus
`Erythematosus, EXPERT REVIEWS IN MOLECULAR MED. 1-28
`(1999)
`Shohei Kishishita et al., Effect of Temperature Shift on Levels
`of Acidic Charge Variants in IgG Monoclonal Antibodies in
`Chinese Hamster Ovary Cell Culture, 119 J. BIOSCIENCE &
`BIOENGINEERING 700-705 (2015)
`Nigel Jenkins, Modifications of Therapeutic Proteins:
`Challenges and Prospects, 53 CYTOTECHNOLOGY 121-125
`(2007)
`Declaration of Carol Basey (submitted in European Patent
`Office, Case No. T 2522/10-3304) (June 2013)
`Declaration of Gregory Blank (submitted in European Patent
`Office, Case No. T 2522/10-3304) (Jan. 15, 2008)
`Declaration of John Simpson (submitted in European Patent
`Office, Case No. T 2522/10-3304) (June 24, 2013)
`Declaration of Laura Storto (submitted in European Patent
`Office, Case No. T 2522/10-3304) (July 15, 2013)
`Declaration of Dongyuan Wang (submitted in European Patent
`Office, Case No. T 2522/10-3304) (June 29, 2011)
`Declaration of Janet Yang (submitted in European Patent
`Office, Case No. T 2522/10-3304) (June 6, 2013)
`Matthias Brunner, Investigation of the Interactions of Critical
`Scale-Up Parameters (pH, pO2 and pCO2) on CHO Batch
`Performance and Critical Quality Attributes, 40 BIOPROCESS
`BIOSYST. ENG. 251-263 (2017)
`Michael J. Pikal et al., The Effects of Formulation Variables on
`the Stability of Freeze-Dried Human Growth Hormone, 8
`PHARM. RES. 427-436 (1991)
`- i -
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`Exhibit Name
`
`Srinivasa Rao et al., Separation of Monoclonal Antibodies by
`Weak Cation-Exchange Chromatography Using ProPac and
`ProSwift Columns (2010)
`Declaration of Robert J. Gunther, Jr. in support of Motion for
`Admission Pro Hac Vice
`Declaration of Daralyn J. Durie in support of Motion for
`Admission Pro Hac Vice
`
`
`
`
`
`
`- ii -
`
`Patent Owner’s
`Exhibit Number
`2014
`
`
`2015
`
`2016
`
`
`
`
`
`
`
`
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that, on January 3, 2018, I caused a true and correct copy of
`the following materials:
`
` 
`
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of
`Robert J. Gunther, Jr.
`
` Exhibit 2015
`
` Patent Owner’s Exhibit List
`
`to be served via electronic mail on the following attorneys of record:
`
`Amanda Hollis
`KIRKLAND & ELLIS LLP
`amanda.hollis@kirkland.com
`300 North LaSalle, Chicago, IL 60654
`
`Sarah K. Tsou
`KIRKLAND & ELLIS LLP
`sarah.tsou@kirkland.com
`601 Lexington Avenue, New York, NY 10022
`
`Karen Younkins
`KIRKLAND & ELLIS LLP
`karen.younkins@kirkland.com
`333 S. Hope Street, Los Angeles, CA 90071
`
`Katherine Rhoades
`KIRKLAND & ELLIS LLP
`katherine.rhoades@kirkland.com
`300 North LaSalle, Chicago, IL 60654
`
`Pfizer_Genentech_IPRs@kirkland.com
`
`
`- iii -
`
`
`
`
`
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`/Rebecca A. Whitfield/
`Rebecca A. Whitfield
`Reg. No. 73,756
`Wilmer Cutler Pickering Hale and Dorr LLP
`60 State Street
`Boston, MA 02109
`(617) 526-6505
`
`
`
`
`- iv -
`
`